Published in Neurology on April 01, 1996
Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet (2007) 2.53
Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet (1997) 1.96
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A (2013) 1.72
Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet (1998) 1.47
Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist (2012) 1.27
Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. J Neurol Neurosurg Psychiatry (1997) 1.26
Epithelioid malignant peripheral nerve sheath tumor arising in a schwannoma, in a patient with "neuroblastoma-like" schwannomatosis and a novel germline SMARCB1 mutation. Am J Surg Pathol (2012) 1.06
Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol (2011) 1.04
Schwannomatosis involving peripheral nerves: a case report. J Korean Med Sci (2006) 0.99
A case of multiple cutaneous schwannomas; schwannomatosis or neurofibromatosis type 2? J Neurol Neurosurg Psychiatry (2006) 0.99
Sciatic nerve tumor and tumor-like lesions - uncommon pathologies. Skeletal Radiol (2012) 0.93
High-resolution array-CGH profiling of germline and tumor-specific copy number alterations on chromosome 22 in patients affected with schwannomas. Hum Genet (2005) 0.88
Recurrent benign schwannoma of the scalp: Case report. Int J Surg Case Rep (2012) 0.88
Multiple schwannomas: report of two cases. Eur Spine J (2007) 0.86
Ophthalmological manifestations in segmental neurofibromatosis type 1. Br J Ophthalmol (2004) 0.85
Recurrent orbital schwannomas: clinical course and histopathologic correlation. BMC Ophthalmol (2012) 0.83
Retroperitoneal schwannomas. Am J Case Rep (2012) 0.82
Spinal schwannomatosis. Neurology (1997) 0.81
Aberrant axon neurofilaments in schwannomas associated with phacomatoses. Virchows Arch (2003) 0.80
Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies. Acta Otorhinolaryngol Ital (2016) 0.79
Aromatase excess syndrome presenting with prepubertal gynecomastia in an Egyptian child with type 1 neurofibromatosis. Indian J Hum Genet (2013) 0.77
Expanding the mutational spectrum of LZTR1 in schwannomatosis. Eur J Hum Genet (2014) 0.77
Superficial neurofibromas in the setting of schwannomatosis: nosologic implications. Acta Neuropathol (2010) 0.76
Familial Schwannomatosis: A Diagnostic Challenge. J Clin Diagn Res (2017) 0.75
The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis. Hum Genet (2016) 0.75
Multiple Lower Extremity Mononeuropathies by Segmental Schwannomatosis: A Case Report. Ann Rehabil Med (2015) 0.75
Extracranial Trigeminal Schwannomas: A Retrospective Analysis. J Maxillofac Oral Surg (2016) 0.75
Extracranial Head and Neck Schwannomas: Our Experience. Indian J Otolaryngol Head Neck Surg (2015) 0.75
Intraosseous schwannoma in schwannomatosis. Skeletal Radiol (2013) 0.75
Pediatric schwannomatosis, a rare but distinct form of neurofibromatosis. Pediatr Radiol (2015) 0.75
[Hereditary tumor syndromes in neuropathology]. Pathologe (2017) 0.75
Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development. Nat Commun (2017) 0.75
A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas. Childs Nerv Syst (2017) 0.75
Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science (1997) 6.10
Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet (1996) 2.67
CT imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform lesions. Neurology (1998) 2.32
Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Cancer (1995) 2.20
Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet (1997) 1.96
Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nat Genet (1992) 1.84
Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol (1996) 1.52
Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum. J Neurosurg (1993) 1.44
Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet (1999) 1.40
MeCP2 mutations in children with and without the phenotype of Rett syndrome. Neurology (2001) 1.36
Do NF1 gene deletions result in a characteristic phenotype? Am J Med Genet (1997) 1.23
Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol (1991) 1.22
Identification of VAV2 on 9q34 and its exclusion as the tuberous sclerosis gene TSC1. Ann Hum Genet (1995) 1.21
Tuberous sclerosis. Arch Dermatol (1994) 1.20
Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet (1994) 1.17
Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest (1987) 1.14
Clinical and biochemical manifestations of hyaluronidase deficiency. N Engl J Med (1996) 1.11
Novel mutations detected in the TSC2 gene from both sporadic and familial TSC patients. Hum Mol Genet (1996) 1.09
Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res (1992) 1.08
Localization of one gene for tuberous sclerosis within 9q32-9q34, and further evidence for heterogeneity. Am J Hum Genet (1991) 1.06
Grafting genetically modified cells into the rat brain: characteristics of E. coli beta-galactosidase as a reporter gene. Brain Res Mol Brain Res (1989) 1.03
Intramedullary hemorrhage in spinal cord hemangioblastoma. Report of two cases. J Neurosurg (1994) 1.01
Comprehensive mutational analysis of the TSC1 gene: observations on frequency of mutation, associated features, and nonpenetrance. Ann Hum Genet (1998) 1.00
Transplantation of a polymer-encapsulated cell line genetically engineered to release NGF. Exp Neurol (1993) 0.97
Characterization of a complex chromosomal rearrangement in a patient with a typical catlike cry and no other clinical findings of cri-du-chat syndrome. Am J Med Genet (1999) 0.97
Bone marrow transplantation in Maroteaux-Lamy syndrome (MPS type 6): status 40 months after BMT. Birth Defects Orig Artic Ser (1986) 0.93
Optic nerve sarcoidosis. Report of a case. Arch Ophthalmol (1972) 0.93
A clinical study of patients with multiple isolated neurofibromas. J Med Genet (2001) 0.92
An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg (1993) 0.90
Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population. Am J Hum Genet (1995) 0.90
Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids. Neuroscience (1991) 0.88
Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. Neuroreport (1993) 0.84
Retrovirus-mediated gene transfer of beta-nerve growth factor into mouse pituitary line AtT-20. Mol Biol Med (1988) 0.84
Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders. Mol Genet Metab (2012) 0.84
Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF. J Neurosci Res (1993) 0.84
Frequent progesterone receptor immunoreactivity in tuberous sclerosis-associated renal angiomyolipomas. Mod Pathol (1998) 0.82
A point mutation associated with a severe phenotype of neurofibromatosis 2. Ann Neurol (1996) 0.82
Interstitial deletion of the short arm of chromosome 3 (3p14). Am J Med Genet (1986) 0.81
Brachial plexus myoclonus. J Neurol Neurosurg Psychiatry (1985) 0.81
Deep sylvian fissure meningioma without dural attachment in an adult: case report. Neurosurgery (1994) 0.81
Does tuberin function as a tumor suppressor in the cerebral lesions of tuberous sclerosis? Early observations. Brain Pathol (1996) 0.80
Cholesteryl ester storage disease: pathologic changes in an affected fetus. Am J Med Genet (1987) 0.80
Human fetal astrocytes as an ex vivo gene therapy vehicle for delivering biologically active nerve growth factor. Hum Gene Ther (1997) 0.77
The use of genetically altered astrocytes to provide nerve growth factor to adrenal chromaffin cells grafted into the striatum. Brain Res (1991) 0.77
Retinoblastoma, chromosome abnormalities and oncogene expression. Ophthalmic Paediatr Genet (1987) 0.77
A child with neurofibromatosis-1 and a lumbar epidural arteriovenous malformation. J Child Neurol (2000) 0.77
Neurological dimensions of psychiatry. Biol Psychiatry (1985) 0.76
Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson's disease. Brain Res (1994) 0.76
Molecular genetic screening for children at risk of neurofibromatosis 2. Arch Otolaryngol Head Neck Surg (1995) 0.76
Convenience survey regarding autopsy/organ donation education at the 1999 American Medical Association Annual Meeting. Arch Intern Med (2000) 0.75
Human XPMC2H: cDNA cloning, mapping to 9q34, genomic structure, and evaluation as TSC1. Genomics (1997) 0.75
Survival and differentiation within the adult mouse striatum of grafted rat pheochromocytoma cells (PC12) genetically modified to express recombinant beta-NGF. Exp Neurol (1991) 0.75
Some investigations of the effect of a non-ionic surfactant on the diffusion of hydrocortisone across a cellulose acetate membrane. J Pharm Pharmacol (1971) 0.75
Comparison of the in vitro serum microbiological activity of a triple tetracycline tablet, 300 mg B.I.D. with oxytetracyline, 250 mg Q.I.D. J Int Med Res (1981) 0.75
Effect of surfactants on diffusion of drugs across membranes. Nat New Biol (1972) 0.75
A study of the formulation of steroidal suspensions. J Pharm Pharmacol (1972) 0.75
Dissolution of hydrocortisone. J Pharm Sci (1972) 0.75
Issues in implementing prenatal screening for cystic fibrosis: results of a working conference. Genet Med (2001) 0.75
A de novo translocation in a family with a balanced reciprocal chromosomal translocation. Clin Genet (1986) 0.75
Biopharmaceutical aspects of the design of steroidal dosage forms. Pharmazie (1973) 0.75